The immune response to Leishmania: Mechanisms of parasite control and evasion

International Journal for Parasitology

Volumn 28, Issue 1, 1998, Pages 121-134

  Bogdan, Christian ^a   Röllinghoff, Martin ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Evasion mechanisms; Glycoinositolphospholipids; Interleukin 12; Leishmania; Lipophosphoglycan; Macrophages; Nitric oxide synthase; Persistence of parasites; T helper lymphocytes (Th1, Th2); Transforming growth factor

Indexed keywords

GLYCOPHOSPHOLIPID; INTERLEUKIN 12; LIPOPHOSPHOGLYCAN; TRANSFORMING GROWTH FACTOR BETA;

ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; CONFERENCE PAPER; DISEASE TRANSMISSION; HELPER CELL; HOST PARASITE INTERACTION; HOST RESISTANCE; LEISHMANIASIS; NONHUMAN; PARASITE VIRULENCE; SURVIVAL; T LYMPHOCYTE ACTIVATION;

ANIMALS; CELL DIFFERENTIATION; COMPLEMENT SYSTEM PROTEINS; CYTOKINES; LEISHMANIA; LEISHMANIASIS; LYMPHOCYTE ACTIVATION; MACROPHAGES; MODELS, IMMUNOLOGICAL; PHAGOCYTOSIS; T-LYMPHOCYTES;

EID: 0031940263     PISSN: 00207519     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0020-7519(97)00169-0     Document Type: Conference Paper

References (117)

1. [1] Borovsky PF. On sart sore. Voen-Med Z (Mil Med J) 1898; 11: 925-941.
2. [2] Sacks DL, Pimenta PFP, McConville MJ, Schneider P, Turco SJ. Stage-specific binding of Leishmania donovani to the sand fly vector midgut is regulated by conformational changes in the abundant surface lipophosphoglycan. J Exp Med 1995; 181: 685-697.
3. [3] Mosser DM, Rosenthal LA. Leishmania-macrophage interactions: multiple receptors, multiple ligands, and diverse cellular responses. Semin Cell Biol 1993; 4: 315-325.
4. [4] Coulson RMR, Smith DF. Isolation of genes showing increased or unique expression in the infective promastigotes of Leishmania major. Mol Biochem Parasitol 1990; 40: 63-76.
5. [5] Pogue GP, Koul S, Lee NS, Dwyer DM, Nakhasi HL. Identification of intra- and interspecific Leishmania genetic polymorphisms by arbitrary primed polymerase chain reactions and use of polymorphic DNA to identify differentially regulated genes. Parasitol Res 1995; 81: 282-290.
6. [6] Smith DF, Rangarajan D. Cell surface components of Leishmania: identification of a novel parasite lectin. Glycobiology 1995; 5: 161-166.
7. [7] Zhang WW, Charest H, Ghedin E, Matlashewski G. Identification and overexpression of the A2 amastigote-specific protein in Leishmania donovani. Mol Biochem Parasitol 1996; 78: 79-90.
8. [8] Handman E, Schnur LF, Spithill TW, Mitchell GF. Passive transfer of Leishmania lipopolysaccharide confers parasite survival in macrophages. J Immunol 1986; 137: 3608-3613.
9. [9] Elhay M, Kelleher M, Bacic A, et al. Lipophosphoglycan expression and virulence in ricin-resistant variants of Leishmania major. Mol Biochem Parasitol 1990; 40: 255-268.
10. [10] McNeely TB, Tolson DL, Pearson TW, Turco SJ. Characterization of Leishmania donovani variant clones using anti-lipophosphoglycan monoclonal antibodies. Glycobiology 1990; 1: 63-69.
11. [11] Liu X, Chang K-P. Extrachromosomal genetic complementation of surface metalloproteinase (gp63)-deficient Leishmania increases their binding to macrophages. Proc Natl Acad Sci USA 1992; 89: 4991-4995.
12. [12] McGwire B, Chang KP. Genetic rescue or surface metalloproteinase (gp63) deficiency in Leishmania amazonensis variants increases their infection of macrophages at the early phase. Mol Biochem Parasitol 1994; 66: 345-353.
13. [13] Descoteaux A, Luo Y, Turco SJ, Beverly SM. Aspecialized pathway affecting virulence glycoconjugates of Leishmania. Science 1995; 269: 1869-1872.
14. [14] Titus RD, Gueiros-Filho FJ, de Freitas LAR, Beverley SM. Development of a safe live Leishmania vaccine line by gene replacement. Proc Natl Acad Sci USA 1995; 92: 10267-10271.
15. [15] Coombs G. Leishmania cysteine proteinases: structure, functions and possibilities for exploitation. Abstr 3. Acta Parasitol Turc 1997; 21(Suppl): 5.
16. [16] Desjardins M, Descoteaux A. Inhibition of phagolysosomal biogenesis by the Leishmania lipophosphoglycan. J Exp Med 1997; 185: 2061-2068.
17. [17] McMaster R, Joshi P, Kelly B. Targeted deletion of gp63 metalloproteinase genes in L. major. Abstr 102. Acta Parasitol Turc 1997; 21(Suppl): 55.
18. [18] Zhang W., Matlashewski G. Loss of virulence in Leishmania donovani deficient in an amastigote-specific protein, A2. Proc Natl Acad Sci USA 1997; 94: 8807-8811.
19. [19] Müller I, Garcia-Sanz JA, Titus R, Behin R, Louis J. Analysis of the cellular parameters of the immune responses contributing to resistance and susceptibility of mice to infection with the intracellular parasite, Leishmania major. Immunol Rev 1989; 112: 95-113.
20. [20] Squires KE, Schreiber RD, McElrath MJ, Rubin BY, Anderson SL, Murray HW. Experimental visceral leishmaniasis: role of endogenous IFN-γ in host defense and tissue granulomatous response. J Immunol 1989; 143: 4244-4249.
21. [21] Liew FY, O'Donnell CA. Immunology of leishmaniasis. Adv Parasitol 1993; 32: 161-259.
22. [22] Kemp M, Kurtzhals JAL, Kharazmi A, Theander TG. Dichotomy in the human CD4+ T-cell response to Leishmania parasites. APMIS 1994; 102: 81-88.
23. [23] Ghalib HW, Whittle JA, Kubin M, et al. IL-12 enhances Th1-type responses in human Leishmania donovani infections. J Immunol 1995; 154: 4623-4629.
24. [24] Reiner SL, Locksley RM. The regulation of immunity to Leishmania major. Ann Rev Immunol 1995; 13: 151-177.
25. [25] Bacellar O, Brodskyn C, Guerreiro J, et al. Interleukin-12 restores interferon-γ production and cytotoxic responses in visceral leishmaniasis. J Infect Dis 1996; 173: 1515-1518.
26. [26] Bogdan C, Gessner A, Solbach W, Röllinghoff M. Invasion, control, and persistence of Leishmania parasites. Curr Opin Immunol 1996; 8: 517-525.
27. [27] Mattner F, Magram J, Ferrante J, et al. Genetically resistant mice lacking interleukin-12 are susceptible to infection with Leishmania major and mount a polarized Th2 cell response. Eur J Immunol 1996; 26: 1553-1559.
28. [28] Vieira LQ, Goldschmidt M, Nashleanas M, Pfeffer K, Mak T, Scott P. Mice lacking the TNF receptor p55 fail to resolve lesions caused by infection with Leishmania major, but control parasite replication. J Immunol 1996; 157: 827-835.
29. [29] Lohoff M, Ferrick D, Mittrücker H-W, et al. Interferon regulatory factor-1 is required for a T helper 1 immune response in vivo. Immunity 1997; 6: 681-689.
30. [30] Murray HW. Endogenous interleukin-12 regulates acquired resistance in experimental visceral leishmaniasis. J Infect Dis 1997; 175: 1477-1479.
31. [31] Murray HW. Susceptibility of Leishmania to oxygen intermediates and killing by normal macrophages. J Exp Med 1981; 153: 1302-1315.
32. [32] Green SJ, Nacy CA. Antimicrobial and immunopathologic effects of cytokine-induced nitric oxide synthesis. Curr Opin Infect Dis 1993; 6: 384-396.
33. [33] Stenger S, Thüring H, Röllinghoff M, Bogdan C. Tissue expression of inducible nitric oxide synthase is closely associated with resistance to Leishmania major. J Exp Med 1994; 180: 783-793.
34. [34] Wei X-q, Charles IG, Smith A, et al. Altered immune responses in mice lacking inducible nitric oxide synthase. Nature 1995; 375: 408-411.
35. [35] Bogdan C. Of microbes, macrophages and NO. Behring Inst Res Commun 1997; 99: 58-72.
36. [36] Sadick MD, Heinzel FP, Holaday BJ, Pu RT, Dawkins RS, Locksley RM. Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody. Evidence for a T cell-dependent, interferon-γ-independent mechanism. J Exp Med 1990; 171: 115-127.
37. [37] Barral A, Barral-Netto M, Yong EC, Brownell CE, Twardzik DR, Reed SG. Transforming growth factor β as a virulence mechanism for Leishmania braziliensis. Proc Natl Acad Sci USA 1993; 90: 3442-3446.
38. [38] Barral A, Teixeira M, Reis P, et al. Transforming growth factor-β in human cutaneous leishmaniasis. Am J Pathol 1995; 147: 947-954.
39. [39] Soares MBP, David JR, Titus RG. An in vitro model for infection with Leishmania major that mimics the immune response in mice. Infect Immun 1997; 65: 2837-2845.
40. [40] Puentes SM, da Silva RP, Sacks DL, Hammer CH, Joiner KA. Serum resistance of metacyclic stage Leishmania major promastigotes is due to release of C5b-9. J Immunol 1990; 145: 4311-4316.
41. [41] Hermoso T, Fishelson Z, Becker S, Hirschberg K, Jaffe CL. Leishmanial protein kinases phosphorylate components of the complement cascade. EMBO J 1991; 10: 4061-4067.
42. [42] Sacerdoti-Sierra N, Siman-Tov MM, Shapira M, Jaffe CL. Leishmanial protein kinases and parasite survival. Abstr. 1. Acta Parasitol Turc 1997; 21(Suppl): 3.
43. [43] Brittingham A, Morrison CJ, McMaster WR, McGwire BS, Chang K-P, Mosser DM. Role of the Leishmania surface protease gp63 in complement fixation, cell adhesion and resistance to complement-mediated lysis. J Immunol 1995; 155: 3102-3111.
44. [43a] Rosenthal LA, Sutterwala FS, Kehrli ME, Mosser, DM. Leishmania mayor-human macrophage interactions: cooperation between Mac-1 (CD11b/CD18) and complement receptor type 1 (CD35) in promastigote adhesion. Infect Immun 1996; 64: 2206-2215.
45. [44] Wright SD, Silverstein SC. Receptors for C3b and C3bi promote phagocytosis but not the release of toxic oxygen from human phagocytes. J Exp Med 1983; 158: 2016-2023.
46. [44a] da Silva R, Hall BF, Joiner KA, Sacks DL. CR1, the C3b receptor, mediates binding of infective metacydic promastigotes to human macrophages. J Immunol 1989; 143: 617-622.
47. [45] Mosser DM, Edelson PJ. The third component of complement (C3) is responsible for the intracellular survival of Leishmania major. Nature 1987; 327: 329-331.
48. [46] Titus RG,Theodos CM, Shankar A, Hall LR. Interactions between Leishmania major and macrophages. In: Zwilling T, Eisenstein T, editors. Macrophage-pathogen interactions. New York: Marcel Dekker, 1993;437-459.
49. [47] Moll H., Ritter U, Flohé S, Erb K, Bauer C, Blank C. Cutaneous leishmaniasis: a model for analysis of the immunoregulation by accessory cells. Med Microbiol Immunol 1996; 184: 163-168.
50. [48] Moore KJ, Matlashewski G. Intracellular infection by Leishmania donovani inhibits macrophage apoptosis. J Immunol 1994; 152: 2930-2937.
51. [49] Alexander J, Russel DG. The interaction of Leishmania species with macrophages. Adv Parasitol 1992; 31: 175-253.
52. [50] Guy RA, Melosevic M. Comparison of receptors required for entry of Leishmania major amastigotes into macrophages. Infect Immun 1993; 61: 1553-1558.
53. [51] Culley FJ, Harris RA, Kaye PM, McAdam KPWJ, Raynes JG. C-Reactive protein binds to a novel ligand on Leishmania donovani and increases uptake into human macrophages. J Immunol 1996; 156: 4691-4696.
54. [52] Blank C, Bogdan C, Bauer C, Erb K, Moll H. Murine epidermal Langerhans cells do not express inducible nitric oxide synthase. Eur J Immunol 1996; 26: 792-796.
55. [53] Mirkovich AM, Galelli A, Allison AC, Modabber FZ. Increased myelopoiesis during Leishmania major infection in mice: generation of "safe targets", a possible way to evade the effector immune mechanism. Clin Exp Immunol 1986; 64: 1-7.
56. [54] Bogdan C, Nathan C. Modulation of macrophage function by transforming growth factor-β, interleukin 4 and interleukin 10. Ann NY Acad Sci 1993; 685: 713-739.
57. [55] Hoover DL, Nacy CA. Macrophage activation to kill Leishmania tropica: defective intracellular killing of amastigotes by macrophages elicited with sterile inflammatory agents. J Immunol 1984; 132: 1487-1493.
58. [56] Sunderkötter C, Kunz M, Steinbrink K, et al. Resistance of mice to experimental leishmaniasis is associated with more rapid appearance of mature macrophages in vitro and in vivo. J Immunol 1993; 151: 4891-4901.
59. [57] Murray HW. Blood monocytes: differing effector role in experimental visceral versus cutaneous leishmaniasis. Parasitol Today 1994; 10: 220-223.
60. [58] Aebischer T. Recurrent cutaneous leishmaniasis: a role for persistent parasites. Parasitol Today 1994; 10: 25-28.
61. [59] Stenger S, Donhauser N, Thüring H, Röllinghoff M, Bogdan C. Reactivation of latent leishmaniasis by inhibition of inducible nitric oxide synthase. J Exp Med 1996; 183: 1501-1514.
62. [60] Leclercq V, Lebastard M, Belkaid Y, Louis J, Milon G. The outcome of the parasitic process initiated by Leishmania infantum in laboratory mice. A tissue-dependent pattern controlled by the Lsh and MHC loci. J Immunol 1996; 157: 4537-4545.
63. [61] McNeely TB, Turco SJ. Requirement of lipophosphoglycan for intracellular survival of Leishmania donovani within human monocytes. J Immunol 1990; 144: 2745-2750.
64. [62] Chan J, Fujiwara T, Brennan P, et al. Microbial glycolipids: possible virulence factors that scavenge oxygen radicals. Proc Natl Acad USA 1989; 86: 2453-2457.
65. [63] Medina-Acosta E, Karess RE, Schwartz R, Russell DG. The promastigote surface protease (gp63) of Leishmania is expressed but differentially processed and localized in the amastigote stage. Mol Biochem Parasitol 1989; 37: 263-274.
66. [64] Ilg T, Harbecke D, Overath P. The lysosomal gp63-related protein in Leishmania mexicana amastigotes is a soluble metalloproteinase with an acidic pH optimum. FEBS Lett 1993; 327: 103-107.
67. [65] Seay MB, Heard PL, Chaudhuri G. Surface Zn-proteinase as a molecule for defense of Leishmania mexicana amazonensis promastigotes against cytolysis inside macrophage phagolysosomes. Infect Immun 1996; 64: 5129-5137.
68. [66] Noronha FSM, Ramalho-Pinto FJ, Horta MF. Cytolytic activity in the genus Leishmania: involvement of a putative pore-forming protein. Infect Immun 1996; 64: 3975-3982.
69. [67] McConville MJ, Ralton JE. Developmentally regulated changes in the cell surface architecture of Leishmania parasites. Behring Inst Res Commun 1997; 99; 34-43.
70. [68] Ismail SO, Skeiky YAW, Bhatia A, Omara-Opyene LA, Gedamu L. Molecular cloning, characterization, and expression in Escherichia coli of iron superoxide dismutase cDNA from Leishmania donovani chagasi. Infect Immun 1994; 62: 657-664.
71. [69] Bogdan C, Röllinghoff M, Solbach M. Evasion strategies of Leishmania parasites. Parasitol Today 1990; 6: 183-187.
72. [70] Ilg T, Stierhof YD, McConville MJ, Overath P. Purification, partial characterization and immunolocalization of a proteophosphoglycan secreted by Leishmania mexicana amastigotes. Eur J Cell Biol 1995; 66: 205-215.
73. [71] Ilg T, Stierhof YD, Craik D, Simpson R, Handman E, Bacic A. Purification and structural characterization of a filamentous, mucin-like proteophosphoglycan secreted by Leishmania parasites. J Biol Chem 1996; 271: 21583-21596.
74. [72] Buchmüller-Rouiller Y, Mauèl J. Impairment of the oxidative metabolism of mouse peritoneal macrophages by intracellular Leishmania spp. Infect Immun 1987; 55: 587-593.
75. [73] Olivier M, Brownsey RW, Reiner NE. Defective stimulus-response coupling in human monocytes infected with Leishmania donovani is associated with altered activation and translocation of protein kinase C. Proc Natl Acad Sci USA 1992; 89: 7481-7485.
76. [74] Passwell JH, Shor R, Smolen J, Jaffe CL. Infection of human monocytes by Leishmania results in a defective oxidative burst. Int J Exp Pathol 1994; 75: 277-284.
77. [75] Descoteaux A, Turco SJ. The lipophosphoglycan of Leishmania and macrophage protein kinase C. Parasitol Today 1993; 9: 468-471.
78. [76] Giorgione JR, Turco SJ, Epand RM. Transbilayer inhibition of protein kinase C by the lipophosphoglycan from Leishmania donovani. Proc Natl Acad Sci USA 1996; 93: 11634-11639.
79. [77] Sorensen AL, Hey AS, Kharazmi A. Leishmania major surface protease gp63 interferes with the function of human monocytes and neutrophils in vitro. APMIS 1994; 102: 265-271.
80. [78] McNeely TB, Rosen G, Londner MV, Turco SJ. Inhibitory effects on protein kinase C activity by lipophosphoglycan fragments and glycosylphosphatidyl-inositol antigens of the protozoan parasite Leishmania. Biochem J 1989; 259: 601-604.
81. [79] Frankenburg S, Leibovici V, Mansbach N, Turco SJ. Effect of glycolipids of Leishmania parasites on human monocyte activity. J Immunol 1990; 145: 4284-4289.
82. [80] Proudfoot L, Nikolaev AV, Feng G-J, et al. Regulation of the expression of nitric oxide synthase and leishmanicidal activity by glycoconjugates of Leishmania lipophosphoglycan in murine macrophages. Proc Natl Acad Sci USA 1996; 93: 10984-10989.
83. [81] Proudfoot L, O'Donnell CA, Liew FY. Glycoinositolphospholipids of Leishmania major inhibit nitric oxide synthesis and reduce leishmanicidal activity in murine macrophages. Eur J Immunol 1995; 25: 745-750.
84. [82] Jardim A, Funk V, Caprioli RM, Olafson RW. Isolation and characterization of the Leishmania donovani kinetoplastid membrane protein-11, a major immunoreactive membrane glycoprotein. Biochem J 1995; 305: 307-313.
85. [82a] Melby PC, Andrade-Narvaez FJ, Darnell BJ, Valencia-Pacheco G, Tryon VV, Palomo-Cetina A. Increased expression of proinflammatory cytokines in chronic lesions of human cutaneous leishmaniasis. Infect Immun 1994; 62: 837-842.
86. [83] Barral-Netto M, Barral A, Brownell CE, et al. Transforming growth factor-β in leishmanial infection: a parasite escape mechanism. Science 1992; 257: 545-548.
87. [84] Scharton-Kersten T, Afonso LCC, Wysocka M, Trinchieri G, Scott P. IL-12 is required for natural killer cell activation and subsequent Thelper 1 cell development in experimental leishmaniasis. J Immunol 1995; 154: 5320-5330.
88. [85] Carrera L, Gazzinelli RT, Badolato R, et al. Leishmania promastigotes selectively inhibit interleukin-12 induction in bone marrow-derived macrophages from susceptible and resistant mice. J Exp Med 1996; 183: 515-526.
89. [85a] Sartori A, Oliveira MAP, Scott P, Trinchieri G. Metacyclogenesis modulates the ability of Leishmania promastigotes to induce IL-12 production in human mononuclear cells. J Immunol 1997; 159: 2849-2857.
90. [86] Akuffo H, Maasho K, Blostedt M, Höjeberg B, Britton S, Bakhiet M. Leishmania aethiopica derived from diffuse leishmaniasis patients preferentially induce mRNA for interleukin 10, while those from localised leishmaniasis patients induce interferon-γ. J Infect Dis 1997; 175: 737-741.
91. [87] Ritter U, Moll H, Laskay T, et al. Differential expression of chemokines in skin lesions of patients with localized and diffuse American cutaneous leishmaniasis. J Infect Dis 1996; 173: 699-709.
92. [88] Reiner NE. Parasite accessory cell interactions in murine leishmaniasis. I. Evasion and stimulus-dependent suppression of the macrophage interleukin 1 response by Leishmania donovani. J Immunol 1987; 138: 1919-1925.
93. [89] Reiner NE, Ng W, Wilson CB, McMaster WR, Burchett SK. Modulation of in vitro monocyte cytokine responses to Leishmania donovani. Interferon-γ prevents parasite-induced inhibition of interleukin-1 production and primes monocytes to respond to Leishmania by producing both tumor necrosis factor-α and interleukin 1. J Clin Invest 1990; 85: 1914-1924.
94. [90] Descoteaux A, Matlashewski G. c-fos and tumor necrosis factor gene expression in Leishmania donovani-infected macrophages. Mol Cell Biol 1989; 9: 5223-5227.
95. [91] Hatzigeorgiou DE, Geng J, Zhu B, et al. Lipophosphoglycan from Leishmania suppresses agonist-induced interleukin-1β gene expression in human monocytes via a unique promotor sequence. Proc Natl Acad Sci USA 1996; 93: 14708-14713.
96. [92] Reiner SL, Zheng S, Wang Z-E, Stowring L, Locksley RM. Leishmania promastigotes evade interleukin 12 (IL-12) induction by macrophages and stimulate a broad range of cytokines from CD4+ T cells during initiation of infection. J Exp Med 1994; 179: 447-456.
97. [93] Belkaid Y, Sacks D. Flow cytometric analysis of cytokine production by inflammatory macrophages: selective impairment of IL-12 induction in Leishmania infected cells. Abstr 28. Acta Parasitol Turc 1997; 21(Suppl): 23.
98. [94] Liew FY. The role of nitric oxide in host-parasite interactions. 13th European Immunology Meeting, Amsterdam, 1997.
99. [95] Wilson ME, Sandor M, Blum AM, et al. Local suppression of IFN-γ in hepatic granulomas correlates with tissue-specific replication of Leishmania chagasi. J Immunol 1996; 156: 2231-2239.
100. [96] Kaye PM. Costimulation and the regulation of anti-microbial immunity. Immunol Today 1995; 16: 423-427.
101. [97] Reiner NE. Altered cell signaling and mononuclear phagocyte deactivation during intracellular infection. Immunol Today 1994; 15: 374-381.
102. [98] De Souza-Leao S, Lang T, Prina E, Hellio R, Antoine JC. Intracellular Leishmania amazonensis amastigotes internalize and degrade MHCclass II molecules of their host cells. J Cell Sci 1995; 108: 3219-3231.
103. [99] Kaye PM, Rogers NJ, Curry AJ, Scott JC. Deficient expression of co-stimulatory molecules on Leishmania-infected macrophages. Eur J Immunol 1994; 24: 2850-2854.
104. [100] Saha B, Das G, Vohra H, Ganguly NK, Mishra GC. Macrophage-T cell interaction in experimental visceral leishmaniasis: failure to express costimulatory molecules on Leishmania-infected macrophages and its implications in the suppression of cell-mediated immunity. Eur J Immunol 1995; 25: 2492-2498.
105. [101] Locksley RM, Reiner SL, Hatam F, Littman DR, Killeen N. Helper T cells without CD4: control of leishmaniasis in CD4-deficient mice. Science 1993; 261: 1448-1451.
106. [102] Wolfram M, Fuchs M, Stierhof Y-D, Overath P. Antigen presentation by Leishmania mexicana-infected macrophages: activation of helper T cells by a model parasite antigen secreted in to the parasitophorous vacuole or expressed on the amastigote surface. Eur J Immunol 1996; 26: 3153-3162.
107. [103] Prina E, Lang T, Glaichenhaus N, Antoine J-C. Presentation of the protective parasite antigen LACK by Leishmania-infected macrophages. J Immunol 1996; 156: 4318-4327.
108. [104] Kima PE, Soong L, Chicharro C, Ruddle NH, McMahon-Pratt D. Leishmania-infected macrophages sequester endogenously synthesized parasite antigens from presentation to CD4+ T cells. Eur J Immunol 1996; 26: 3163-3169.
109. [105] Bogdan C, Röllinghoff M. The impact of the type 1 and type 2 T helper cell concept on novel vaccine design with emphasis on protection against Leishmania parasites. In: Kaufmann SHE, editor. Concepts in vaccine development. Berlin: Walter de Gruyter, 1996;143-180.
110. [106] Launois P, Maillard I, Pingel S, et al. IL-4 rapidly produced by Vβ4Vα8 CD4+ T cells instructs Th2 development and susceptibility to Leishmania major in BALB/c mice. Immunity 1997; 6: 541-549.
111. [107] Demant P, Lipoldova M, Svobodova M. Resistance to Leishmania major in mice. Science 1996; 274: 1392.
112. [108] Gorham JD, Güler ML, Steen RG, et al. Genetic mapping of a murine locus controlling development of T helper 1/T helper 2 type responses. Proc Natl Acad Sci USA 1996; 93: 12467-12472.
113. [109] Beebe AM, Mauze S, Schork NJ, Coffman RL. Serial backcross mapping of multiple loci associated with resistance to Leishmania major in mice. Immunity 1997; 6: 551-557.
114. [110] Roberts LJ, Baldwin TM, Curtis JM, Handman E, Foote SJ. Resistance to Leishmania major is linked to the H2 region on chromosome 17 and to chromosome 9. J Exp Med 1997; 185: 1705-1710.
115. [111] Hall LR, Titus RG. Sandfly vector saliva selectively modulates macrophage functions that inhibit killing of Leishmania major and nitric oxide production. J Immunol 1995; 155: 3501-3506.
116. [112] David J, Soares N, Satoskar A, et al. Immunomodulatory properties of maxadilan, a peptide derived from sandfly saliva. Abstr 364. Acta Parasitol Turc 1997; 21(Suppl): 174.
117. [113] Warburg A., Waitumbi J. Sandfly saliva and leishmaniosis. Abstr 122. Acta Parasitol Turc 1997; 21(Suppl): 67.